Rep. Cummings seeks House hearing on Turing Pharma CEO; Amgen and Allergan say study shows their Avastin biosimilar effective in lung cancer

@FiercePharma: Otsuka prepares to roll out two-drug combo for colorectal cancer. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI: Novo to build a $78M insulin pen plant in Iran. FiercePharmaManufacturing story | Follow @EricPFierce

> Amgen ($AMGN) and Allergan ($AGN) said a late-stage study showed their biosimilar candidate of Roche ($RHHBY) blockbuster Avastin was as effective as the original in lung cancer. Story

> ViiV Healthcare says a data from a Phase IIIb/IV study met the endpoint in patients with suppressed HIV when they switched to its once daily Triumeq from an antiretroviral therapy. Release

> Depomed Wednesday reported a decision from patent regulators that it said will help it in its patent-infringement lawsuits against Endo Pharmaceuticals ($ENDP) and Purdue Pharma and their competing painkillers. Report

> U.S. Rep. Elijah E. Cummings is asking the House to hold a hearing with Martin Shkreli, whose company Turing Pharma recently jacked up the price by 5000% of a pill whose users tend to be AIDS sufferers and cancer patients. Release

> England's price watchdog NICE has recommended approval of Daiichi Sankyo's bloodthinner Lixiana to prevent blood clots in adult patients with a certain heart rhythm disorder. Story

Medical Device News

@FierceMedDev: ICYMI: St. Jude nabs CE mark for Infinity DBS for movement disorders, awaits U.S. launch before year end. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceBiotech: Should Martin Shkreli be allowed to play the Good Samaritan defense? Commentary | Follow @VarunSaxena2

@EmilyWFierce: Human Longevity joins with South African insurer for $250 exome sequencing service. FierceDiagnostics article | Follow @EmilyWFierce

> CliniCloud gets $5M seed round to launch connected medical kit at Best Buy. News

> Institute of Medicine makes suggestions for improving accuracy of medical diagnoses. Item

> Four key medical device recalls of 2015. Report

Biotech News

@FierceBiotech: FierceBiotech Radio with @JohnCFierce on Turing Pharma, Martin Shkreli and the magic of Twitter. More | Follow @FierceBiotech

@JohnCFierce: These Twitter controversies are intense. On CNN, Sky News, CBC and other radio shows to discuss being called a moron. Cheers. | Follow @JohnCFierce

@DamianFierce: The best thing about ABC's exclusive Shkreli story was that NBC ran it 15 minutes earlier. | Follow @DamianFierce

> Amgen and Allergan clear Phase III with an Avastin biosimilar, looking to unseat a blockbuster. More

> Scholar Rock hopes to one-up pharma titans with a muscle-building drug. News

> OncoGenex's drug misses the mark in pancreatic cancer. Story

Biotech Research News

> Uppsala's 'smart' robot tests new cancer drug combos. News

> Epigenomic combo shows promise in mouse model of pancreatic cancer. Story

> An arthritis drug demos potential to help reverse Alzheimer's disease. More

> Experimental drug amps up Afinitor's punch against pancreatic cancer. Article

> Imperial team targets a key culprit involved in Parkinson's. News

Diagnostics News

> Roche's influenza A and B tests get federal permission to be used at the point-of-care. Story

> LabCorp, China's Fosun Pharma, lead Asia-heavy $15B investment in Ativa Medical. More

> Rumor: Private equity owners looking to sell Swiss diagnostics player Unilabs for $1.7B. Article

> Human Longevity joins with South African insurer for $250 exome sequencing service. News

> Sequenom appoints new CEO amid diversification. Story

Pharma Marketing News

> Emmy co-host Mario Lopez spotlights Valeant's Jublia on the red carpet. News

> Fretting about potential Humira pain for AbbVie? Take heart in potential cost cuts. Story

> Apple's ad blocking heats up debate, but what does it mean for pharma? Article

> IMS Health finds mHealth mobile app 'prescriptions' on the rise. Story

> Otsuka prepares to roll out two-drug combo for colorectal cancer. Item

And Finally... Arkansas intends to go ahead and use for lethal injection a Sun Pharma drug despite the company's objection. Story

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.